XTL Biopharma Sets Shareholder Meeting for July 22
Ticker: XTLB · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
Related Tickers: XTLB
TL;DR
XTL Bio holding shareholder meeting July 22nd, important votes coming up.
AI Summary
XTL Biopharmaceuticals Ltd. announced on June 12, 2024, that it will hold its Annual and Extraordinary General Meeting of Shareholders on July 22, 2024, in Bnei Brak, Israel. The company is furnishing related documents, including the Notice and Proxy Statement, in connection with this meeting.
Why It Matters
This meeting is crucial for shareholders to vote on important company matters and potentially influence the future direction of XTL Biopharmaceuticals.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a shareholder meeting and does not contain new financial or operational risks.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Registrant
- June 12, 2024 (date) — Announcement Date
- July 22, 2024 (date) — Meeting Date
- Bnei Brak, Israel (location) — Meeting Location
- Doron Tikotzky Kantor Gutman & Amit Gross (company) — Company's Attorneys
FAQ
What is the purpose of the Annual and Extraordinary General Meeting of Shareholders?
The purpose is for shareholders to vote on matters presented by the company, as detailed in the Notice and Proxy Statement being furnished.
Where will the Annual and Extraordinary General Meeting of Shareholders be held?
The meeting will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, located at 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
When is the Annual and Extraordinary General Meeting of Shareholders scheduled?
The meeting is scheduled to be held on July 22, 2024.
What type of issuer is XTL Biopharmaceuticals Ltd. according to this filing?
XTL Biopharmaceuticals Ltd. is filing as a Foreign Private Issuer.
What documents is XTL Biopharmaceuticals Ltd. furnishing in connection with the meeting?
The company is furnishing a copy of the Notice and Proxy Statement.
Filing Stats: 380 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-06-12 16:05:07
Filing Documents
- ea0207646-6k_xtlbio.htm (6-K) — 14KB
- ea020764601ex99-1_xtlbio.htm (EX-99.1) — 225KB
- ea020764601ex99-2_xtlbio.htm (EX-99.2) — 28KB
- ea020764601ex99-3_xtlbio.htm (EX-99.3) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- ex99-1_003.jpg (GRAPHIC) — 6KB
- ex99-1_004.jpg (GRAPHIC) — 5KB
- ex99-1_005.jpg (GRAPHIC) — 7KB
- ex99-1_006.jpg (GRAPHIC) — 4KB
- ex99-1_007.jpg (GRAPHIC) — 5KB
- ex99-2_001.jpg (GRAPHIC) — 3KB
- ex99-3_001.jpg (GRAPHIC) — 960KB
- ex99-3_002.jpg (GRAPHIC) — 606KB
- 0001213900-24-052080.txt ( ) — 2480KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: June 12, 2024 /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 3